Voyageur Pharmaceuticals (VYYRF)
OTHER OTC:VYYRF
VYYRF Stock Chart & Stats
$0.13
>-$0.01(-10.37%)
At close: 4:00 PM EST
$0.13
>-$0.01(-10.37%)
Day’s Range― - ―
52-Week Range$0.08 - $0.25
Previous CloseN/A
Volume200.00
Average Volume (3M)5.52K
Market Cap
$15.47M
Enterprise Value$21.20M
Total Cash (Recent Filing)$267.05K
Total Debt (Recent Filing)$40.00K
Price to Earnings (P/E)―
Beta-17.26
Next Earnings
Apr 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding178,586,980
10 Day Avg. Volume7,500
30 Day Avg. Volume5,516
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue1.81K
Enterprise Value/Gross Profit-17.34
Enterprise Value/Ebitda-6.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Mineral-derived Medical Ingredient FocusSpecializing in mineral-sourced inputs for radiology contrast positions the company in a durable, regulated segment of healthcare imaging. Qualification and regulatory pathways create high switching costs and product stickiness if approvals and clinical adoption are achieved, supporting long-term revenue potential.
Low, Improving LeverageA very low and falling debt burden materially reduces solvency risk and interest obligations, preserving flexibility to pursue development and commercialization. This conservative capital structure is a durable strength if management can stabilize cash burn or secure non-debt financing.
Control Of Mineral Assets And Processing CapabilitiesOwning and developing mineral deposits plus in-house processing/qualification can provide supply security, cost control and barriers to entry. These vertically integrated capabilities support long-term commercialization of specialty mineral products once regulatory and market qualification hurdles are cleared.
Bears Say
Severe Unprofitability And Negative Gross ProfitPersistent, large losses and negative gross profit indicate the business is not covering direct costs, undermining the viability of current operations. Continued unprofitability erodes equity, limits reinvestment capacity and requires strategic change or substantial funding to reach sustainable margins.
Worsening Cash Burn; High Funding RiskA sharp increase in operating cash outflows creates acute funding pressure and raises the likelihood of dilutive financing or constrained execution. This structural cash burn shortens runway, limiting the firm's ability to complete commercialization without external capital or immediate cost restructuring.
Very Low Revenue And Lack Of ScaleRevenue remains immaterial versus fixed and development costs, preventing economies of scale and margin improvement. The unproven commercial traction means long lead times to monetize assets and elevated execution risk as the company attempts to move from development to sustainable sales.
Voyageur Pharmaceuticals News
VYYRF FAQ
What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was $0.08 and its highest was $0.25 in the past 12 months.
What is Voyageur Pharmaceuticals’s market cap?
Voyageur Pharmaceuticals’s market cap is $15.47M.
When is Voyageur Pharmaceuticals’s upcoming earnings report date?
Voyageur Pharmaceuticals’s upcoming earnings report date is Apr 24, 2026 which is in 14 days.
How were Voyageur Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Voyageur Pharmaceuticals overvalued?
According to Wall Street analysts Voyageur Pharmaceuticals’s price is currently Overvalued.
Does Voyageur Pharmaceuticals pay dividends?
Voyageur Pharmaceuticals does not currently pay dividends.
What is Voyageur Pharmaceuticals’s EPS estimate?
Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyageur Pharmaceuticals have?
Voyageur Pharmaceuticals has 178,586,980 shares outstanding.
What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
Currently, no hedge funds are holding shares in VYYRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products. It holds 100% interest in three barium sulfate deposits, including two properties suitable in grade for the pharmaceutical barite marketplace located in British Columbia, Canada; and interests in a high-grade iodine, lithium, and bromine brine project in Utah, the United States. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---